Replimune Group (NASDAQ:REPL) had its price objective hoisted by Barclays from $29.00 to $50.00 in a research note published on Thursday, The Fly reports. The firm currently has an overweight rating on the stock.
A number of other equities research analysts also recently commented on REPL. Zacks Investment Research upgraded Replimune Group from a sell rating to a hold rating in a report on Saturday, October 10th. Roth Capital increased their price target on Replimune Group from $30.00 to $50.00 and gave the stock a buy rating in a report on Wednesday. HC Wainwright upgraded Replimune Group from a neutral rating to a buy rating and increased their price target for the stock from $25.00 to $54.00 in a report on Thursday. Chardan Capital increased their price target on Replimune Group from $30.00 to $48.00 and gave the stock a buy rating in a report on Wednesday. Finally, SVB Leerink increased their price target on Replimune Group from $27.00 to $44.00 and gave the stock an outperform rating in a report on Thursday. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $42.06.
NASDAQ REPL opened at $40.98 on Thursday. The stock has a 50-day simple moving average of $24.54 and a 200 day simple moving average of $20.54. The company has a market capitalization of $1.65 billion, a PE ratio of -24.69 and a beta of 3.20. The company has a current ratio of 22.54, a quick ratio of 22.54 and a debt-to-equity ratio of 0.14. Replimune Group has a 12 month low of $8.58 and a 12 month high of $46.30.
In other news, insider Pamela Esposito sold 16,000 shares of the stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $32.90, for a total transaction of $526,400.00. Following the transaction, the insider now owns 128,700 shares in the company, valued at $4,234,230. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Colin Love sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $23.44, for a total value of $351,600.00. Following the transaction, the chief operating officer now owns 1,042,488 shares in the company, valued at approximately $24,435,918.72. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,000 shares of company stock worth $1,013,250. 50.90% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in REPL. BNP Paribas Arbitrage SA increased its stake in Replimune Group by 119.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,071 shares of the company’s stock worth $41,000 after acquiring an additional 2,212 shares during the period. Great West Life Assurance Co. Can bought a new position in Replimune Group during the 2nd quarter worth $42,000. Strs Ohio increased its stake in Replimune Group by 28.6% during the 2nd quarter. Strs Ohio now owns 2,700 shares of the company’s stock worth $67,000 after acquiring an additional 600 shares during the period. Alliancebernstein L.P. increased its stake in Replimune Group by 43.1% during the 1st quarter. Alliancebernstein L.P. now owns 18,600 shares of the company’s stock worth $185,000 after acquiring an additional 5,600 shares during the period. Finally, Prudential Financial Inc. bought a new position in Replimune Group during the 2nd quarter worth $217,000. Institutional investors own 60.86% of the company’s stock.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
See Also: What is a SEC Filing?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.